BioPharma Credit


Market Cap$1,277m

Last Close $0.94

BPCR was incorporated in the UK in October 2016. It aims to generate predictable income for shareholders over the long term through a diversified portfolio of loans and other instruments, backed by royalties or other cash flows derived from sales of approved life sciences products. This includes senior secured notes, royalty debt instruments and priority royalty tranches.

More BioPharma Credit content >

Investment summary

BioPharma Credit (BPCR) has entered into a new senior secured loan agreement for up to US$50m to be provided to UroGen Pharma, a Nasdaq-listed biotech company focused on the treatment of urothelial and speciality cancers. BPCR and BioPharma fund V will each invest US$37.5m in the first tranche and up to a further US$12.5m available to be drawn by end-2022. Following the transaction, BPCR is fully invested and would require additional external capital for new investments (by a further drawdown of its credit facility or a new share issue).

Content on BioPharma Credit
BioPharma Credit – executive interview
Investment companies | Edison TV | 4 October 2022
Biopharma Credit – New transaction of up to US$50m
Investment companies | research Update | 16 March 2022
Biopharma Credit – Fully invested after recent transactions
Investment companies | research Update | 10 January 2022
View more
Register to receive research on BioPharma Credit as it is published
Investment companies
Access more Investment companies content
Share price graph
Price performance
Actual (1.5) (0.6) (4.5)
Relative* 4.4 3.7 2.0
52-week high/low US$1.0/US$0.9
*% relative to local index
Key management
Alexander Perfall VP, Investor Relations & Public Affairs

You may also be interested in…